Table 3. Comparison of outcomes of myasthenia gravis after extended thymectomy.
| The postintervention status | Overall (n=109) | Subxiphoid approach (n=58) | Right-sided approach (n=51) | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| CSR | 42 | 38.5 | 23 | 39.7 | 19 | 37.3 | ||
| PR | 14 | 12.8 | 8 | 13.8 | 6 | 11.8 | ||
| MM | 40 | 36.7 | 21 | 36.2 | 19 | 37.3 | ||
| I | 2 | 18.3 | 1 | 1.7 | 1 | 1.9 | ||
| U | 5 | 4.6 | 2 | 3.4 | 3 | 5.9 | ||
| W | 3 | 2.8 | 2 | 3.4 | 1 | 1.9 | ||
| E | 3 | 2.8 | 1 | 1.7 | 2 | 3.9 | ||
| Effective treatment of MG (n)a | 98 | 89.9 | 53 | 91.4 | 45 | 88.2 | ||
| Ineffective treatment of MG (n)b | 11 | 10.1 | 5 | 8.6 | 6 | 11.8 | ||
| Overall | 109 | 100 | 58 | 53.2 | 51 | 46.8 | ||
| Z | −0.486 | |||||||
| P | 0.627 | |||||||
Effects according to the American MGFA (19): CSR, complete stable remission; PR, pharmacological remission; MM, minimal manifestation; I, improved; U, unchanged; W, worse; E, exacerbation; MG, myasthenia gravis. a, CSR + PR + MM + I; b, U + W + E + D.